Results From First-In-Human Clinical Trial of RP-A501 (AAV9:LAMP2B) Gene Therapy Treatment for Danon Disease

Within the last 24 months, I have financial relationship(s) or affiliation(s) with a manufacturer, marketer, reseller, or distributor of a healthcare product or service involved in the management of patients with any cardiovascular disease to include devices, drugs, and digital health care products listed below:

• Consultant Fee/Honoraria/Speaker's Bureau (Personal) - AstraZenca; Merck/Schering Plough; Sanofi-Aventis; Actelion, Cytokinetics, EBR Systems, Ionis, Viking, Windtree, Zensun, Mesoblast